Albumin-binding MR blood pool contrast agent improves diagnostic performance in human brain tumour: Comparison of two contrast agents for glioblastoma

European Radiology

Volumn 23, Issue 4, 2013, Pages 1093-1101

  Puig, Josep ^a   Blasco, Gerard ^a   Essig, Marco ^b   Daunis I Estadella, Josep ^c   Laguillo, Gemma ^a   Quiles, Ana María ^a   Remollo, Sebastián ^a   Bergmann, Karsten ^d   Joly, Carme ^a   Bernado, Lluis ^a   Sánchez González, Javier ^e   Pedraza, Salvador ^a  

^a HOSPITAL JOSEP TRUETA   (Spain)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF GIRONA   (Spain)

^d BAYER PHARMA AG   (Germany)

^e PHILIPS HEALTHCARE   (United States)

Author keywords

Brain neoplasms; Contrast media; Gadolinium; Glioblastoma; Magnetic resonance imaging

Indexed keywords

GADOBUTROL; GADOFOSVESET;

ADULT; AGED; ARTICLE; BRAIN TUMOR; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTRAST TO NOISE RATIO; FEMALE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SIGNAL NOISE RATIO;

EID: 84878612010     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-012-2678-9     Document Type: Article

References (20)

1. Giesel FL, Mehndiratta A, Essig M (2010) High-relaxivity contrast-enhanced magnetic resonance neuroimaging: a review. Eur Radiol 20:2461-2474
2. Smirniotopoulos JG, Murphy FM, Rushing EJ, Rees JH, Schroeder JW (2007) Patterns of contrast enhancement in the brain and meninges. Radiographics 27:525-551
3. Jensen TR, Schmainda KM (2009) Computer-aided detection of brain tumor invasion using multiparametric MRI. J Magn Reson Imaging 30:481-489
4. Essig M, Weber MA, von Tengg-Kobligk H, Knopp MV, Yuh WT, Giesel FL (2006) Contrast-enhanced magnetic resonance imaging of central nervous system tumors: agents, mechanisms, and applications. Top Magn Reson Imaging 17:89-106
5. Colosimo C, Manfredi R, Tartaglione T (1997) Contrast enhancement issues in the MR evaluation of the central nervous system. Eur Radiol Suppl 5:231-237
6. Tombach B, Heindel W (2002) Value of 1.0-M gadolinium chelates: review of preclinical and clinical data on gadobutrol. Eur Radiol 12:1550-1556
7. Attenberger UI, Runge VM, Jackson CB et al. (2009) Comparative evaluation of lesion enhancement using 1 M gadobutrol vs. 2 conventional gadolinium chelates, all at a dose of 0.1 mmol/kg, in a rat brain tumor model at 3 T. Investig Radiol 44:251-256
8. Mohs AM, Lu ZR (2007) Gadolinium (III)-based blood-pool contrast agents for magnetic resonance imaging: status and clinical potential. Expert Opin Drug Deliv 4:149-164
9. Farooki A, Narra V, Brown J (2004) Gadofosveset EPIX/Schering. Curr Opin Investig Drugs 5:967-976
10. Caravan P (2009) Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action. Acc Chem Res 42:851-862
11. Seitz RJ, Wechsler W (1987) Immunohistochemical demonstration of serum proteins in human cerebral gliomas. Acta Neuropathol 73:145-152
12. Essig M, Rohrer M, Giesel F et al. (2010) Human brain tumor imaging with a protein-binding MR contrast agent: initial experience. Eur Radiol 20:218-226
13. Maravilla KR, Maldjian JA, Schmalfuss IM et al. (2006) Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents. Radiology 240:389-400
14. Fleiss JL (1981) Statistical methods for rates and proportions, 2nd edn. Wiley, New York
15. Adzamli K, Yablonskiy DA, Chicoine MR et al. (2003) Albumin-binding MR blood pool agents as MRI contrast agents in an intracranial mouse glioma model. Magn Reson Med 49:586-590
16. Wintersperger BJ, Runge VM, Tweedle MF, Jackson CB, Reiser MF (2009) Brain tumor enhancement in magnetic resonance imaging: dependency on the level of protein binding of applied contrast agents. Investig Radiol 44:89-94
17. Els T, Bockhorst K, Hoehn-Berlage M (1993) NMR contrast enhancement of brain tumours: Comparison of the BBB tracer GdDTPA and tumour-selective contrast agent MnTPPS. MAGMA 1:126-133
18. Hahn G, Sorge I, Gruhn B et al. (2009) Pharmacokinetics and safety of gadobutrol enhanced magnetic resonance imaging in pediatric patients. Investig Radiol 44:776-783
19. Senft C, Bink A, Franz K, Vatter H, Gasser T, Seifert V (2011) Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol 12:997-1003
20. Yuh WT, Tali ET, Nguyen HD, Simonson TM, Mayr NA, Fisher DJ (1995) The effect of contrast dose, imaging time, and lesion size in the MR detection of intracerebral metastasis. AJNR Am J Neuroradiol 16:373-380